Treatment of tumors using antibodies specific anti-L1

A binding molecule capable of binding to L1, (a) being selected from the group consisting of single chain antibodies, scFv, multimers of scFv such as diabodies, triabodies or tetrabodies, antibody fragments, Fab, Tandabs, Flexibodies, bispecific and chimeric antibodies and / or (b) comprising at least one lg domain, and wherein the binding molecule capable of binding to L1: (i) is characterized in its complementarity determining regions (CDRs) having the following sequences: LCDR1: RASQDISNYLN (SEQ ID No .: 24), LCDR2: YTSRLHS (SEQ ID No .: 25), LCDR3: QQGNTLPWT (SEQ ID No .: 26), HCDR1: RYWML (SEQ ID No .: 27), HCDR2: EINPRNDRTNYNEKFKT ( SEQ ID No .: 28) and HCDR3: GGGYAMDY (SEQ ID No .: 29), and whose binding molecule binds to L1 with an affinity (KD) of at least 10-10 M, or (ii) is characterized their complementarity determining regions (CDRs) having the following sequences: LCDR1: QDISNY (SEQ ID No .: 30), LCDR2: YTS, LCDR3: QQGNTLPWT (SEQ I D No .: 31), HCDR1: GYTFTRYW (SEQ ID No .: 32), HCDR2: INPRNDRT (SEQ ID No .: 33), and HCDR3: ALGGGYAMDY (SEQ ID No .: 34), and whose binding molecule L1 binds with an affinity (KD) of at least 10-10 M.